BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J 2019;7:642-50. [PMID: 31210942 DOI: 10.1177/2050640619840149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. Journal of the Formosan Medical Association 2020;119:1019-40. [DOI: 10.1016/j.jfma.2020.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
2 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
3 Bhuvanakrishna T, Wakefield S. A commentary on "Liver transplantation for Hepatitis C patients in the era of direct-acting antiviral treatment: A retrospective cohort study". Int J Surg 2020;76:62-3. [PMID: 32105896 DOI: 10.1016/j.ijsu.2020.02.023] [Reference Citation Analysis]
4 Peters MG, Kottilil S, Terrault N, Amara D, Husson J, Huprikar S, Florman S, Sulkowski MS, Durand CM, Luetkemeyer AF, Rogers R, Grab J, Haydel B, Blumberg E, Dove L, Emond J, Olthoff K, Smith C, Fishbein T, Masur H, Stock PG. Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre- or post-liver transplant. Am J Transplant. 2020;. [PMID: 33277801 DOI: 10.1111/ajt.16427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Von den Hoff DW, Berden FAC, Schellekens AFA. If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. United European Gastroenterol J 2021;9:1101-2. [PMID: 34687156 DOI: 10.1002/ueg2.12167] [Reference Citation Analysis]
6 Magro F, Drenth JP. Gastroenterological features of COVID-19 and the role of the United European Gastroenterology Journal. United European Gastroenterol J 2020;8:505-6. [PMID: 32450786 DOI: 10.1177/2050640620926832] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Medrano LM, Berenguer J, Salgüero S, González-García J, Díez C, Hontañón V, Garcia-Broncano P, Ibañez-Samaniego L, Bellón JM, Jiménez-Sousa MA, Resino S. Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. Front Med (Lausanne) 2021;8:615342. [PMID: 33598470 DOI: 10.3389/fmed.2021.615342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Isfordink CJ, Brakenhoff SM, van Dijk M, van der Valk M, de Knegt RJ, Arends JE, Drenth JP; HepNed study group. Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C. BMJ Open Gastroenterol 2020;7:e000396. [PMID: 32377367 DOI: 10.1136/bmjgast-2020-000396] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Pozza R, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Eradicating hepatitis C virus: The APRN's role. Nurse Pract 2019;44:16-27. [PMID: 31567700 DOI: 10.1097/01.NPR.0000586008.23422.2c] [Reference Citation Analysis]
10 van Dijk M, Drenth JPH; HepNed study group. Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination. J Viral Hepat 2020;27:1270-83. [PMID: 32964615 DOI: 10.1111/jvh.13399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zappulo E, Scotto R, Buonomo AR, Maraolo AE, Pinchera B, Gentile I. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opin Pharmacother 2020;21:261-73. [PMID: 31914336 DOI: 10.1080/14656566.2019.1697674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Elsharkawy A, Samir R, El-Kassas M. Fibrosis regression following hepatitis C antiviral therapy. World J Hepatol 2022; 14(6): 1120-1130 [DOI: 10.4254/wjh.v14.i6.1120] [Reference Citation Analysis]
13 Jain M. Hepatitis C treatment in the era of directly acting antivirals: an encouraging scenario. Trop Doct 2020;50:334-6. [PMID: 32631174 DOI: 10.1177/0049475520936878] [Reference Citation Analysis]
14 Berkan-Kawińska A, Piekarska A, Janczewska E, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Berak H, Horban A, Zarębska-Michaluk D, Pabjan P, Buczyńska I, Pazgan-Simon M, Dybowska D, Halota W, Pawłowska M, Klapaczyński J, Mazur W, Czauż-Andrzejuk A, Socha Ł, Laurans Ł, Garlicki A, Sitko M, Jaroszewicz J, Citko J, Dobracka B, Krygier R, Białkowska-Warzecha J, Tronina O, Belica-Wdowik T, Baka-Ćwierz B, Flisiak R. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver Int 2021;41:1789-801. [PMID: 33655628 DOI: 10.1111/liv.14858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]